

**Table 10.6a**  
**Immunosuppression Use for Induction, 1999 to 2008**  
**Recipients with Intestine Transplants**

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
<b>Transplants</b>	73	82	113	107	116	152	178	175	198	185
<b>With Immunosuppression Info</b>	71	80	112	106	116	149	167	169	194	182
<b>Induction Drugs</b>										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	0.0%	1.3%	0.0%	0.9%	1.7%	2.7%	1.8%	0.6%	0.5%	0.0%
OKT3	9.9%	5.0%	6.3%	2.8%	1.7%	1.3%	3.6%	14.2%	17.5%	15.4%
Thymoglobulin	4.2%	0.0%	12.5%	31.1%	45.7%	18.8%	15.6%	18.9%	23.7%	33.5%
Zenapax	49.3%	55.0%	24.1%	12.3%	17.2%	12.8%	13.8%	17.2%	9.8%	8.2%
Simulect	1.4%	12.5%	13.4%	13.2%	1.7%	0.7%	3.0%	3.0%	2.1%	0.5%
Campath	0.0%	0.0%	0.0%	1.9%	8.6%	19.5%	22.2%	21.3%	13.4%	18.1%
<b>No Induction Drugs Recorded</b>	39.4%	31.3%	43.8%	39.6%	25.0%	45.6%	45.5%	40.8%	51.0%	40.1%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.